GlassScriptPhysician profile
John D Chapman
NPI 1184268617
$15,019.77
in general payments reported to CMS, 2019-2025
33 companies · $3,501 in 2025
The $3,501 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $3,355 · 2023: $3,602 · 2024: $3,798 · 2025: $3,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,900.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,956.50 | 2021-2025 | Cabenuva, Apretude, Rukobia |
| Gilead Sciences, INC. | $3,423.22 | 2021-2025 | Biktarvy, Descovy, Yeztugo |
| Theratechnologies INC. | $1,188.69 | 2021-2025 | Trogarzo, Egrifta |
| Napo Pharmaceuticals INC | $896.67 | 2021-2025 | Mytesi |
| Novo Nordisk INC | $882.25 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $771.71 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Emd Serono, INC. | $428.76 | 2022-2025 | Serostim |
| Lilly USA, LLC | $366.22 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Antares Pharma, INC. | $350.57 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $319.44 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $240.45 | 2021-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $213.85 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $137.80 | 2021-2022 | |
| Janssen Products, LP | $107.83 | 2022 | |
| Janssen Biotech, INC. | $96.09 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $79.46 | 2023 | |
| Janssen Pharmaceuticals, INC | $70.80 | 2022-2024 | Spravato |
| Endo Pharmaceuticals INC. | $58.50 | 2021-2022 | |
| Madrigal Pharmaceuticals | $51.73 | 2025 | Rezdiffra |
| Eisai INC. | $40.72 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.92 | 2022-2023 | Quviviq |
| Hologic Sales and Service, LLC | $38.07 | 2023-2024 | Aptima |
| Abbvie INC. | $35.79 | 2024 | |
| Tolmar, INC. | $35.43 | 2025 | Jatenzo |
| Vertex Pharmaceuticals Incorporated | $30.64 | 2025 | |
| Exact Sciences Corporation | $28.59 | 2023 | Cologuard Collection Kit |
| Almatica Pharma LLC | $28.21 | 2022 | |
| Pfizer INC. | $20.37 | 2025 | |
| Glaxosmithkline, LLC. | $18.02 | 2023 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $17.93 | 2024 | Nexletol |
| Medtronic, INC. | $17.30 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.12 | 2023 | Trulance, Xifaxan |
| Acerus Pharmaceuticals Corporation | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.